I'm LongbridgeAI, I can summarize articles.Updated data show emavusertib achieves a 71% ORR in BTKi-naïve and 26% ORR in BTKi-experienced PCNSL patients, with promising early results in CLL. Regulatory guidance supports potential accelerated approval, but continued development depends on securing additional funding.Original document: Curis, Inc. [CRIS] Press release — Jul. 22 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Updated data show emavusertib achieves a 71% ORR in BTKi-naïve and 26% ORR in BTKi-experienced PCNSL patients, with promising early results in CLL. Regulatory guidance supports potential accelerated approval, but continued development depends on securing additional funding.
Original document: Curis, Inc. [CRIS] Press release — Jul. 22 2026